title: [The recurrence of hepatitis C virus after liver transplantation].
abstract: The main indication of the Hungarian Liver Transplant Program is liver cirrhosis caused by hepatitis C.
  
  
  OBJECTIVE
  Authors present the results of liver transplantations performed due to HCV infection.
  
  
  METHODS
  The data (donor-, recipient-, perioperative characteristics, survival, serum titer of C RNA, histology) of 111 HCV positive recipients were evaluated, that are 37.6% of the 295 patients, who were transplanted since 1995 till the closure of this report.
  
  
  RESULTS
  Twenty-two (22) of them (20%) died in the early postoperative period, for other reasons, before the recurrence of the HCV was detectable. Among the 89 HCV-positive patients the recurrence of the HCV is still not detected in 16 cases (18%), and there is a histology-proven recurrence in 73 cases (82%). In 40 cases (56%) the viral recurrence was proven within 1 year after OLT, while in 32 cases (44%) over 1 year. The cumulative 1, 3, 5, and 10 years patient survival is 73%, 67%, 56% and 49%, among HCV-positive patients and 80%, 74%, 70% and 70% among HCV-negatives. The difference is significant. The cumulative graft survival at the same time points is 72%, 66%, 56% and 49% among HCV-positives and 76%, 72%, 68% and 68% among HCV-negatives, which is a non-significant difference. The serum titer of HCV-RNA was significantly higher among those HCV-patients who had an early viral recurrence within 1 year, compared to those who had a late one. In case of an early HCV-recurrence the Knodell-score was significantly higher in the 6 months posttransplant biopsy than that of in case of late viral recurrence, however, less fibrosis was observed in early recurrence.
  
  
  CONCLUSIONS
  An early HCV recurrence can be expected in case of an older donor, with a marginal or fatty liver graft transplanted with a higher transfusion need and having an acute rejection treated with steroid bolus in the postoperative period. The protocol of the postoperative antiviral treatment differs from the average: the so-called "stop-rule" cannot be applied, since less then 10% of the recipients are expected to turn to HCV-PCR-negative due to the immunosuppression. The combined interferon + ribavirin treatment is maintained in spite of RNA-positive state, further, a second or third course of treatment might also be applied. The prolonged and--in case if necessary--repeated antiviral treatment prevents fibrosis, and therefore rate of retransplantation need. The better is the general state of the patient the results of a secondary liver transplantation are better as well. MELD-score can help to set the exact timing for a re-OLT.
authors.affiliation: Semmelweis Egyetem, Altalános Orvostudományi Kar, Transzplantációs és Sebészeti Klinika, Budapest, Baross u. 23-25., 1082. nemes@trans.sote.hu
authors.forename: Balázs
authors.initials: B
authors.lastname: Nemes
authors.forename: Eniko
authors.initials: E
authors.lastname: Sárváry
authors.forename: Zsuzsa
authors.initials: Z
authors.lastname: Gerlei
authors.forename: János
authors.initials: J
authors.lastname: Fazakas
authors.forename: Attila
authors.initials: A
authors.lastname: Doros
authors.forename: Andrea
authors.initials: A
authors.lastname: Németh
authors.forename: Dénes
authors.initials: D
authors.lastname: Görög
authors.forename: Imre
authors.initials: I
authors.lastname: Fehérvári
authors.forename: Zoltán
authors.initials: Z
authors.lastname: Máthé
authors.forename: Zsuzsa
authors.initials: Z
authors.lastname: Gálffy
authors.forename: Alajos
authors.initials: A
authors.lastname: Pár
authors.forename: János
authors.initials: J
authors.lastname: Schuller
authors.forename: László
authors.initials: L
authors.lastname: Telegdy
authors.forename: János
authors.initials: J
authors.lastname: Fehér
authors.forename: Gábor
authors.initials: G
authors.lastname: Lotz
authors.forename: Zsuzsa
authors.initials: Z
authors.lastname: Schaff
authors.forename: Péter
authors.initials: P
authors.lastname: Nagy
authors.forename: Jeno
authors.initials: J
authors.lastname: Járay
authors.forename: Gabriella
authors.initials: G
authors.lastname: Lengyel
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D018572:Disease-Free Survival; D004359:Drug Therapy, Combination; D005260:Female; D006526:Hepatitis C / Q000150:complications* / Q000175:diagnosis* / Q000188:drug therapy; D006801:Humans; D007372:Interferons / Q000627:therapeutic use; D053208:Kaplan-Meier Estimate; D008103:Liver Cirrhosis / Q000601:surgery* / Q000821:virology; D016031:Liver Transplantation; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D012086:Reoperation; D012189:Retrospective Studies; D012254:Ribavirin / Q000627:therapeutic use; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D012254:Ribavirin; D007372:Interferons